CILOSTAZOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27N5O2
Molecular Weight	369.4607
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1CCC2=C(N1)C=CC(OCCCCC3=NN=NN3C4CCCCC4)=C2

InChI

InChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

HIDE SMILES / InChI

Molecular Formula	C20H27N5O2
Molecular Weight	369.4607
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11830753

Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 61 Target ID: CHEMBL2094125 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824	Inhibitor 8504		0.57 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Intermittent claudication 12 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824	Palliative		Approved 8583	CILOSTAZOL Approved Use Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
701 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
13724 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
3.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020863s011lbl.pdf			CILOSTAZOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31401	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31401
ChemicalBook	CB2362876	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2362876
eMolecules	27518122	https://www.emolecules.com/cgi-bin/more?vid=27518122
eMolecules	535670	https://www.emolecules.com/cgi-bin/more?vid=535670
MolPort	MolPort-001-758-007	https://www.molport.com/shop/molecule-link/MolPort-001-758-007
Selleck Chemicals	Cilostazol	http://www.selleckchem.com/products/Cilostazol.html
ZINC	ZINC000001552174	http://zinc15.docking.org/substances/ZINC000001552174

PubMed

Title	Date	PubMed
New treatment options in intermittent claudication: the US experience.	2001 Apr	11355276
Cilostazol: a novel treatment option in intermittent claudication.	2001 Apr	11355274
A new treatment for peripheral arterial disease.	2001 Apr	11340018
[Pressure wire guide provisional coronary stent implantation].	2001 Apr	11337928
Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?	2001 Feb	11219570
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty.	2001 Jan	11324805
Intermittent claudication: effective medical management of a common circulatory problem.	2001 Jun 28	11434895
Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.	2001 Jun 28	11434894
Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.	2001 Mar 15	11323002
Treatment of intermittent claudication with pentoxifylline and cilostazol.	2001 Mar 15	11286146
Antithrombotic therapy for prevention of pneumonia.	2001 May	11380774
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.	2001 May	11376832
Management of peripheral arterial disease and intermittent claudication.	2001 Nov-Dec	11757887
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.	2002 Aug	12177649
Polymorphic forms of cilostazol.	2002 Aug	12154319
Can claudication be improved with medication?	2002 Dec	12478498
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.	2002 Dec	12473004
Pharmacologic therapy for peripheral arterial disease and claudication.	2002 Dec	12469066
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.	2002 Dec	12463722
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.	2002 Dec 15	12480040
Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.	2002 Feb	11805237
Cilostazol.	2002 Feb 1	11862634
Current medical therapies for patients with peripheral arterial disease: a critical review.	2002 Jan	11812407
The pharmacology of cilostazol.	2002 Mar	12180353
Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans.	2002 Mar	11922271
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.	2002 Mar	11892686
Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.	2002 Mar	11861782
The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats.	2002 Mar 15	12148698
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.	2002 Mar-Apr	11951094
Management of patients with intermittent claudication.	2002 Nov	12469984
Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.	2002 Nov-Dec	12463615
New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.	2002 Oct	12352320
A paclitaxel-eluting stent for the prevention of coronary restenosis.	2003 Apr 17	12700373
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.	2003 Feb	12624709

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of cilostazol tablets is 100 mg b.i.d. taken at least half an hour before or 2 hours after breakfast and dinner.

Route of Administration: Oral

In Vitro Use Guide

In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 uM while it showed a highly sensitive and all-or-none type inhibition response from 25 uM in PFA-100.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:03:59 GMT 2025` Edited by `admin` on `Mon Mar 31 18:03:59 GMT 2025`
Record UNII	N7Z035406B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CILOSTAZOL

Official Name

English

PLETAL

Preferred Name

English

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Common Name

English

CILOSTAZOL [MI]

Common Name

English

OPC-21

Code

English

2(1H)-QUINOLINONE, 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)-3,4-DIHYDRO-

Systematic Name

English

CILOSTAZOL [USP-RS]

Common Name

English

NSC-758936

Code

English

CILOSTAZOL [JAN]

Common Name

English

Cilostazol [WHO-DD]

Common Name

English

OPC-13013

Code

English

CILOSTAZOL [VANDF]

Common Name

English

CILOSTAZOL [USAN]

Common Name

English

CILOSTAZOL [MART.]

Common Name

English

CILOSTAZOL [USP MONOGRAPH]

Common Name

English

cilostazol [INN]

Common Name

English

CILOSTAZOL [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744